Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today ...

today announced new positive data from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel), in patients with relapsed or refractory multiple myeloma (RRMM). These data ...

Overall response rate (ORR) was 97% (114/117) with a complete response/stringent complete response (CR/sCR) rate of 68% (79/117) and a very good partial response or higher (>VGPR) rate of 85% (100/117 ...

(NASDAQ: ACLX) has just released new positive data from its pivotal phase 2 immagine-1 study of Anitocabtagene Autoleucel ...

Praneeth Reddy Sudalagunta, PhD, discusses a novel generative artificial intelligence pipeline developed to help with the understanding and treatment of multiple myeloma.

Ciara Freeman, MD, PhD, discusses the challenges of incorporating anito-cel into the treatment protocol for patients with multiple myeloma.

An innovative blood cancer treatment regimen could extend remission by seven months on average, according to a clinical trial ...

Pieter Sonneveld, MD, PhD, professor of hematology and chair of the Erasmus MC Cancer Institute in Rotterdam, Netherlands, ...

B-cell maturation antigen (BCMA)-directed bispecific antibodies have tolerable safety profiles in frail patients with relapsed/refractory multiple myeloma (MM), according to a real-world study ...

Reference: Cook G, Ashcroft AJ, Senior E, et al. Ixazomib as consolidation and maintenance versus observation in patients with relapsed multiple myeloma eligible for salvage autologous stem-cell ...

When it comes to relapsed/refractory follicular lymphoma, chimeric antigen receptor (CAR) T-cell therapy has become a go-to ...